Company news

Kura Oncology, Inc. news in 2026

Kura Oncology, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Kura Oncology to Participate in Two Investor Conferences in November

November 13, 2026

Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

November 10, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

November 4, 2026

Kura Oncology to Report Third Quarter Financial Results on November 10

November 3, 2026

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

October 13, 2026

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

October 7, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

A Taste of Mystery: Kura Sushi USA and Crunchyroll Brew Up a New Collab with The Apothecary Diaries

September 17, 2026

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

September 9, 2026

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

September 8, 2026

Kura Oncology to Participate in Three Investor Conferences in September

September 1, 2026

Kura Oncology Reports Second Quarter 2026 Financial Results

August 12, 2026

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

August 11, 2026

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

August 10, 2026

Kura Oncology to Report Second Quarter Financial Results

August 5, 2026

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

July 27, 2026

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

July 14, 2026

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

June 11, 2026

Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

June 8, 2026

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

June 3, 2026

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

June 1, 2026

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

May 26, 2026

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

May 18, 2026

Kura Oncology Reports First Quarter 2026 Financial Results

May 12, 2026

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

May 12, 2026

Kura Oncology to Report First Quarter 2026 Financial Results

May 5, 2026

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

April 24, 2026

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

April 17, 2026

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

April 9, 2026

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

March 4, 2026

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 6, 2026

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

January 10, 2026

Calls in 2026

Decks in 2026